Selected research
Market Structure
Global Blood Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Blood Cancer Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Blood Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Blood Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Blood Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Blood Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Blood Cancer Drugs include Astellas Pharma,, AstraZeneca PLC,, Bayer AG,, Bristol-Myers Squibb Company,, Celgene Corporation,, F.Hoffmann-La Roche,, AbbVie, Amgen, and Pfizer,, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Blood Cancer Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Blood Cancer Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Blood Cancer Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Blood Cancer Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Blood Cancer Drugs Segment by Company
Astellas Pharma,
AstraZeneca PLC,
Bayer AG,
Bristol-Myers Squibb Company,
Celgene Corporation,
F.Hoffmann-La Roche,
AbbVie
Amgen,
Pfizer,
Eli Lilly,
Novartis
Johnson & Johnson,
Takeda Pharmaceutical Company Ltd,
Blood Cancer Drugs Segment by Type
Blood Chemotherapy Drugs
Blood Targeted Therapy Drugs
Blood Cancer Drugs Segment by Application
lymphoma
Multiple Myeloma
Leukemia
Blood Cancer Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Blood Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood Cancer Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Blood Cancer Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Blood Cancer Drugs industry.
Chapter 3: Detailed analysis of Blood Cancer Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Blood Cancer Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Blood Chemotherapy Drugs
- Blood Targeted Therapy Drugs
Applications
- lymphoma
- Multiple Myeloma
- Leukemia
Companies covered
- Astellas Pharma,
- AstraZeneca PLC,
- Bayer AG,
- Bristol-Myers Squibb Company,
- Celgene Corporation,
- F.Hoffmann-La Roche,
- AbbVie
- Amgen,
- Pfizer,
- Eli Lilly,
- Novartis
- Johnson & Johnson,
- Takeda Pharmaceutical Company Ltd,
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Blood Cancer Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Blood Chemotherapy Drugs
- 1.2.3 Blood Targeted Therapy Drugs
- 1.3 Market Analysis by Application
- 1.3.1 Global Blood Cancer Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 lymphoma
- 1.3.3 Multiple Myeloma
- 1.3.4 Leukemia
- 1.4 Global Market Growth Prospects
- 1.5 Global Blood Cancer Drugs Growth Trends by Region
- 1.5.1 Global Blood Cancer Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Blood Cancer Drugs Market Size by Region (2021-2026)
- 1.5.3 Blood Cancer Drugs Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Blood Cancer Drugs Market Dynamics
- 2.1 Blood Cancer Drugs Industry Trends
- 2.2 Blood Cancer Drugs Industry Drivers
- 2.3 Blood Cancer Drugs Industry Opportunities and Challenges
- 2.4 Blood Cancer Drugs Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Blood Cancer Drugs Revenue by Company (2021-2026)
- 3.2 Global Blood Cancer Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Blood Cancer Drugs Key Company Head office and Area Served
- 3.4 Global Blood Cancer Drugs Company, Product Type & Application
- 3.5 Global Blood Cancer Drugs Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Blood Cancer Drugs Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Blood Cancer Drugs Players Market Share by Revenue in 2025
- 3.6.3 2025 Blood Cancer Drugs Tier 1, Tier 2, and Tier 3
4 Blood Cancer Drugs Market by Type
- 4.1 Global Blood Cancer Drugs Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Blood Cancer Drugs Market Size by Type (2021-2032)
- 4.3 Global Blood Cancer Drugs Market Size Share by Type (2021-2032)
5 Blood Cancer Drugs Market by Application
- 5.1 Global Blood Cancer Drugs Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Blood Cancer Drugs Market Size by Application (2021-2032)
- 5.3 Global Blood Cancer Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Astellas Pharma,
- 6.1.1 Astellas Pharma, Company Information
- 6.1.2 Astellas Pharma, Business Overview
- 6.1.3 Astellas Pharma, Blood Cancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Astellas Pharma, Blood Cancer Drugs Product Portfolio
- 6.1.5 Astellas Pharma, Recent Developments
- 6.2 AstraZeneca PLC,
- 6.2.1 AstraZeneca PLC, Company Information
- 6.2.2 AstraZeneca PLC, Business Overview
- 6.2.3 AstraZeneca PLC, Blood Cancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 AstraZeneca PLC, Blood Cancer Drugs Product Portfolio
- 6.2.5 AstraZeneca PLC, Recent Developments
- 6.3 Bayer AG,
- 6.3.1 Bayer AG, Company Information
- 6.3.2 Bayer AG, Business Overview
- 6.3.3 Bayer AG, Blood Cancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Bayer AG, Blood Cancer Drugs Product Portfolio
- 6.3.5 Bayer AG, Recent Developments
- 6.4 Bristol-Myers Squibb Company,
- 6.4.1 Bristol-Myers Squibb Company, Company Information
- 6.4.2 Bristol-Myers Squibb Company, Business Overview
- 6.4.3 Bristol-Myers Squibb Company, Blood Cancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Bristol-Myers Squibb Company, Blood Cancer Drugs Product Portfolio
- 6.4.5 Bristol-Myers Squibb Company, Recent Developments
- 6.5 Celgene Corporation,
- 6.5.1 Celgene Corporation, Company Information
- 6.5.2 Celgene Corporation, Business Overview
- 6.5.3 Celgene Corporation, Blood Cancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Celgene Corporation, Blood Cancer Drugs Product Portfolio
- 6.5.5 Celgene Corporation, Recent Developments
- 6.6 F.Hoffmann-La Roche,
- 6.6.1 F.Hoffmann-La Roche, Company Information
- 6.6.2 F.Hoffmann-La Roche, Business Overview
- 6.6.3 F.Hoffmann-La Roche, Blood Cancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 F.Hoffmann-La Roche, Blood Cancer Drugs Product Portfolio
- 6.6.5 F.Hoffmann-La Roche, Recent Developments
- 6.7 AbbVie
- 6.7.1 AbbVie Company Information
- 6.7.2 AbbVie Business Overview
- 6.7.3 AbbVie Blood Cancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 AbbVie Blood Cancer Drugs Product Portfolio
- 6.7.5 AbbVie Recent Developments
- 6.8 Amgen,
- 6.8.1 Amgen, Company Information
- 6.8.2 Amgen, Business Overview
- 6.8.3 Amgen, Blood Cancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Amgen, Blood Cancer Drugs Product Portfolio
- 6.8.5 Amgen, Recent Developments
- 6.9 Pfizer,
- 6.9.1 Pfizer, Company Information
- 6.9.2 Pfizer, Business Overview
- 6.9.3 Pfizer, Blood Cancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Pfizer, Blood Cancer Drugs Product Portfolio
- 6.9.5 Pfizer, Recent Developments
- 6.10 Eli Lilly,
- 6.10.1 Eli Lilly, Company Information
- 6.10.2 Eli Lilly, Business Overview
- 6.10.3 Eli Lilly, Blood Cancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Eli Lilly, Blood Cancer Drugs Product Portfolio
- 6.10.5 Eli Lilly, Recent Developments
- 6.11 Novartis
- 6.11.1 Novartis Company Information
- 6.11.2 Novartis Business Overview
- 6.11.3 Novartis Blood Cancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Novartis Blood Cancer Drugs Product Portfolio
- 6.11.5 Novartis Recent Developments
- 6.12 Johnson & Johnson,
- 6.12.1 Johnson & Johnson, Company Information
- 6.12.2 Johnson & Johnson, Business Overview
- 6.12.3 Johnson & Johnson, Blood Cancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Johnson & Johnson, Blood Cancer Drugs Product Portfolio
- 6.12.5 Johnson & Johnson, Recent Developments
- 6.13 Takeda Pharmaceutical Company Ltd,
- 6.13.1 Takeda Pharmaceutical Company Ltd, Company Information
- 6.13.2 Takeda Pharmaceutical Company Ltd, Business Overview
- 6.13.3 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Product Portfolio
- 6.13.5 Takeda Pharmaceutical Company Ltd, Recent Developments
7 North America
- 7.1 North America Blood Cancer Drugs Market Size (2021-2032)
- 7.2 North America Blood Cancer Drugs Market Size by Type
- 7.2.1 North America Blood Cancer Drugs Market Size by Type (2021-2026)
- 7.2.2 North America Blood Cancer Drugs Market Size by Type (2027-2032)
- 7.2.3 North America Blood Cancer Drugs Market Share by Type (2021-2032)
- 7.3 North America Blood Cancer Drugs Market Size by Application
- 7.3.1 North America Blood Cancer Drugs Market Size by Application (2021-2026)
- 7.3.2 North America Blood Cancer Drugs Market Size by Application (2027-2032)
- 7.3.3 North America Blood Cancer Drugs Market Share by Application (2021-2032)
- 7.4 North America Blood Cancer Drugs Market Size by Country
- 7.4.1 North America Blood Cancer Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Blood Cancer Drugs Market Size by Country (2021-2026)
- 7.4.3 North America Blood Cancer Drugs Market Size by Country (2027-2032)
- 7.4.4 North America Blood Cancer Drugs Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Blood Cancer Drugs Market Size (2021-2032)
- 8.2 Europe Blood Cancer Drugs Market Size by Type
- 8.2.1 Europe Blood Cancer Drugs Market Size by Type (2021-2026)
- 8.2.2 Europe Blood Cancer Drugs Market Size by Type (2027-2032)
- 8.2.3 Europe Blood Cancer Drugs Market Share by Type (2021-2032)
- 8.3 Europe Blood Cancer Drugs Market Size by Application
- 8.3.1 Europe Blood Cancer Drugs Market Size by Application (2021-2026)
- 8.3.2 Europe Blood Cancer Drugs Market Size by Application (2027-2032)
- 8.3.3 Europe Blood Cancer Drugs Market Share by Application (2021-2032)
- 8.4 Europe Blood Cancer Drugs Market Size by Country
- 8.4.1 Europe Blood Cancer Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Blood Cancer Drugs Market Size by Country (2021-2026)
- 8.4.3 Europe Blood Cancer Drugs Market Size by Country (2027-2032)
- 8.4.4 Europe Blood Cancer Drugs Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Blood Cancer Drugs Market Size (2021-2032)
- 9.2 China Blood Cancer Drugs Market Size by Type
- 9.2.1 China Blood Cancer Drugs Market Size by Type (2021-2026)
- 9.2.2 China Blood Cancer Drugs Market Size by Type (2027-2032)
- 9.2.3 China Blood Cancer Drugs Market Share by Type (2021-2032)
- 9.3 China Blood Cancer Drugs Market Size by Application
- 9.3.1 China Blood Cancer Drugs Market Size by Application (2021-2026)
- 9.3.2 China Blood Cancer Drugs Market Size by Application (2027-2032)
- 9.3.3 China Blood Cancer Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Blood Cancer Drugs Market Size (2021-2032)
- 10.2 Asia Blood Cancer Drugs Market Size by Type
- 10.2.1 Asia Blood Cancer Drugs Market Size by Type (2021-2026)
- 10.2.2 Asia Blood Cancer Drugs Market Size by Type (2027-2032)
- 10.2.3 Asia Blood Cancer Drugs Market Share by Type (2021-2032)
- 10.3 Asia Blood Cancer Drugs Market Size by Application
- 10.3.1 Asia Blood Cancer Drugs Market Size by Application (2021-2026)
- 10.3.2 Asia Blood Cancer Drugs Market Size by Application (2027-2032)
- 10.3.3 Asia Blood Cancer Drugs Market Share by Application (2021-2032)
- 10.4 Asia Blood Cancer Drugs Market Size by Country
- 10.4.1 Asia Blood Cancer Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Blood Cancer Drugs Market Size by Country (2021-2026)
- 10.4.3 Asia Blood Cancer Drugs Market Size by Country (2027-2032)
- 10.4.4 Asia Blood Cancer Drugs Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Blood Cancer Drugs Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Blood Cancer Drugs Market Size by Type
- 11.2.1 South America, Middle East & Africa Blood Cancer Drugs Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Blood Cancer Drugs Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Blood Cancer Drugs Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Blood Cancer Drugs Market Size by Application
- 11.3.1 South America, Middle East & Africa Blood Cancer Drugs Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Blood Cancer Drugs Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Blood Cancer Drugs Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Blood Cancer Drugs Market Size by Country
- 11.4.1 South America, Middle East & Africa Blood Cancer Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Blood Cancer Drugs Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Blood Cancer Drugs Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Blood Cancer Drugs Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst